A Phase 1 interventional study of IBI112 dose1 and IBI112 dose2 in Healthy Subjects, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-19.
Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a the first in human study to evaluate the safety, tolerability, PK and PD of single subcutaneous or intravenous dose of IBI112 in healthy subjects
In this first in human, phase 1, randomized, double-blind, placebo-controlled study, a single subcutaneous or intravenous dose of IBI112 will be administered to 46 healthy subjects.
Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IBI112 SC dose1
Drug: IBI112 dose1
IBI112 SC dose2
Drug: IBI112 dose2
IBI112 SC dose3
Drug: IBI112 dose3
IBI112 IV dose4
Drug: IBI112 dose4
IBI112 IV dose3
Drug: IBI112 dose5
IBI112 SC dose5
Drug: IBI112 dose6
IBI112 IV dose5
Drug: IBI112 dose7
Drug: IBI112 SC dose1 Drug:placebo
Drug: IBI112 SC dose2 Drug:placebo
Drug: IBI112 SC dose3 Drug:placebo
Drug: IBI112 SC dose4 Drug:placebo
Drug: IBI112 IV dose5 Drug:placebo
Drug: IBI112 SC dose6 Drug:placebo
Drug: IBI112 IV dose7 Drug:placebo
Incidence of treatment-emergent adverse events in healthy volunteers with single ascending doses of IBI112
Time frame: Day1 to Day 113 post dose
Maximum Concentration (Cmax) - Pharmacokinetic Assessment
IV dose \& SC dose
Time frame: Day 113
Time to Maximum Concentration (Tmax) - Pharmacokinetic Assessment
SC dose
Time frame: Day 113
Area Under the Curve Extrapolated to Infinity (AUC0-∞) - Pharmacokinetic Assessment
IV dose \& SC dose
Time frame: Day 113
Half-Life (t1/2) - Pharmacokinetic Assessment
IV dose \& SC dose
Time frame: Day 113
Volume of Distribution (Vd) - Pharmacokinetic Assessment
IV dose \& SC dose
Time frame: Day 113
Ran from Aug 2020 to primary completion in Jul 2022, 22 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: IBI112
Innovent Biologics (Suzhou) Co. Ltd. →